Fundraising Fox
Alchemab
Founded 2019 · 73 employees on LinkedIn · 9 known investors
Find your way into Alchemab
Each arrow is one introduction. Sign up to fill in the first one.
Ask Alex Badamchi-Zadeh to introduce you to Jane Osbourn
You →Alex · together at Alchemab Therapeutics →Jane
Sign up to find every way you can get introduced to Alchemab
- Your email: who you already know at Alchemab, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alchemab team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
Founders & leadership
Investors · 9
How we know: RA Capital's portfolio page · the company's own site · funding news · Not right? Tell us
How we know: SV Health Investors's portfolio page · the company's own site · a partner's Signal profile · funding news · Not right? Tell us
How we know: the company's own site · funding news · Not right? Tell us
How we know: Dementia Discovery Fund's portfolio page · funding news · Not right? Tell us
How we know: Lightstone Ventures's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
How we know: Ono Venture Investment, Inc.'s portfolio page · funding news · Not right? Tell us
How we know: funding news · eu-startups.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
In the news
Frequently asked questions
- What does Alchemab do?
- Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
- Who are Alchemab's investors?
- Alchemab's investors include RA Capital, SV Health Investors, DCVC Bio, Dementia Discovery Fund, Lightstone Ventures, Ono Venture Investment, Inc., British Business Bank, British Patient Capital and 1 more.